FDA Clears First Human Trial of Cellular Rejuvenation

By Longevity Lab · Published: July 30, 2026

Based on peer-reviewed research — full source list at the end of this article. This is educational information, not medical advice.

The US Food and Drug Administration (FDA) has cleared the first human trial of a therapy built on partial epigenetic reprogramming, an approach rooted in Epigenetics that tries to return aging cells to a more youthful operating mode without erasing what they are. The clearance, for a phase 1 study, went to Life Biosciences, a company co-founded by Harvard geneticist David Sinclair. Formally, this is the first time the idea of resetting the Biological age of cells has reached testing in people.

What Yamanaka Factors Are, and What Makes Reprogramming “Partial”

In 2006, the Japanese scientist Shinya Yamanaka showed that just four regulatory proteins, now known as the Yamanaka factors (OSKM), can return a mature cell to an embryonic, stem-cell state. He received the Nobel Prize for that discovery in 2012. Full reprogramming has a downside, though: the cell loses its specialization, and uncontrolled growth of such Stem cells risks tumors.

Partial reprogramming is a subtler idea. Switch the factors on briefly and incompletely, so the cell grows younger by its internal settings while staying what it was, say a neuron or a retinal cell. Underneath sits a hypothesis: some age-related change is not irreversible breakage but lost “epigenetic information”, meaning scrambled instructions about which genes should be switched on. If those instructions can be restored, part of aging is in theory reversible. Those same epigenetic marks are what today’s clocks read when they put a number on a person’s biological age, and the main ways of measuring it are compared in Biological age tests: what to measure and how to choose a method.

Why the Eye Was Chosen as the First Target

The experimental gene therapy ER-100 uses three of the four factors, the OSK combination, leaving out the potentially riskier c-Myc, and is delivered by direct injection into the eye. Its first targets are optic neuropathies: glaucoma, the second most common cause of blindness worldwide, and non-arteritic anterior ischemic optic neuropathy (NAION).

The eye was not picked by accident. First, it is relatively isolated from the rest of the body, so the action of the drug is easier to localize and control. Second, vision and the state of the retina can be measured objectively with instruments, so any effect can be tracked. Third, vision loss in these diseases is irreversible and there is almost no effective treatment today, so the potential benefit justifies the experiment. The approach rests on work from Sinclair’s lab, where partial reprogramming restored vision in old mice, and on preclinical primate studies in which the therapy brought lost vision back to near-normal levels.

What Exactly Was Approved, and What Comes Next

What the FDA cleared is a phase 1 trial, the earliest stage of human testing, where the main goal is not efficacy but safety and tolerability. The company plans to enroll its first patients in the coming months and expects first safety results by the end of this year or the start of next. The team is small, but the field behind it is not: interest and investment in the biology of aging now run from large startups to research institutes.

What the FDA Clearance Means for Aging Science

This is an important milestone: the idea of resetting the biological age of cells, until now demonstrated mostly in mice, is reaching human testing for the first time. It is worth staying sober about it:

• phase 1 tests safety above all, not rejuvenation of the body;
• the target is narrow, specific eye diseases rather than aging as a whole;
• reprogramming carries serious risks, cancer among them, and those are exactly what this trial has to keep in check;
• the road from a first trial to an approved therapy usually takes years, and many candidates drop out along the way.

For more on the technology itself, see our review of cellular reprogramming. For now this is grounds for cautious optimism and close attention to the results, not a finished treatment you can sign up for.

How This Fits the Wider Race

The clearance belongs in the context of a broader wave of interest in reversing aging. Recent years have brought large investments and several ambitious companies into the field, each looking for its own route to rejuvenating cells. Reprogramming is only one of those routes: others aim at different mechanisms of cellular aging entirely, such as the shortening DNA caps described in Genetic age and telomeres. Permission to test in humans is a signal that regulators are willing to consider such approaches carefully, provided they start with narrow, controlled questions.

The narrowness of the target is not a weakness here but a deliberate strategy: prove safety on a local, measurable problem, vision, before reaching for aging across the whole body. Aging across the whole body is much harder to read in a single number, which is why it is usually approached indirectly, system by system, with the kind of tools gathered under Biological Clocks & Cellular Aging. If phase 1 goes well, that becomes an argument for other teams working on reprogramming too.

Finally, it is worth remembering the expectations effect. Loud headlines about “the first rejuvenated human” are easy to inflate, so the thing to watch is not the press releases but the published safety and efficacy data, once they exist. Until that data arrives, any confidence in the outcome is premature.

Frequently Asked Questions

Source: The science behind the method: Lu Y, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588:124–129. PubMed →

Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.